Lynn Sullivan is a transformative biopharmaceutical executive and board director whose career has been defined by one consistent theme: creating and scaling markets where none previously existed. With more than 30 years of experience across global pharmaceutical organizations, she has established herself as a category-building leader in obesity, women’s health, and cardiometabolic disease. Her work sits at the intersection of innovation, commercialization, and strategic execution—where breakthrough science meets real-world impact.
Currently serving as Chief Business Officer and Board Member at Rose Pharma Inc., Lynn plays a central role in shaping the company’s growth trajectory. She leads commercial strategy, investor engagement, and partnership development for a Phase 2b-ready asset targeting obesity and acute IBS pain. Her ability to align clinical promise with market opportunity positions the company to compete effectively in highly competitive therapeutic spaces.
In parallel, Lynn is the CEO and President of HealthWise Solutions, where she advises boards, CEOs, and executive teams on commercialization strategy and operational transformation. Through her advisory work, she has helped organizations refine product-market fit, build go-to-market strategies, and expand into new geographies. Notably, she supported the international expansion of Consensus.dk, a Danish life sciences software company, by tailoring its value proposition and accelerating its commercial presence in the United States and beyond.
Lynn’s career reached a defining chapter during her tenure at Novo Nordisk, where she held multiple senior leadership roles across the U.S. and Europe. As Vice President and National Commercial Lead for Obesity, she built and led a commercial organization and drove over $500 million in revenue with more than 30% year-over-year growth. Her leadership was instrumental in shaping today >$100 Billion market potential thru the global commercialization of early GLP-1 therapies, including Ozempic, Saxenda, Wegovy and Rybelsus, products that have since redefined the treatment landscape for obesity and diabetes.
Her influence extended globally as she led marketing strategy across Southeastern Europe, the Middle East, Africa, and Russia, supporting operations in more than 100 countries. In these roles, she demonstrated a rare ability to adapt strategy across diverse healthcare systems while maintaining consistent brand positioning and performance. Her work earned recognition for innovation in launch readiness and global market alignment.
Earlier in her career, Lynn contributed to the successful launch of some of the pharmaceutical industry’s most iconic therapies, including Humira®, Prilosec®, and Actos®. These experiences gave her firsthand exposure to category-defining products and reinforced her ability to translate scientific innovation into commercial success. Over time, she developed a reputation for navigating complex markets and building strategies that deliver both immediate and sustained growth.
Beyond her corporate leadership, Lynn is a respected thought leader and public speaker. She has been featured at conferences and forums addressing women’s leadership in healthcare, chronic weight management, and menopause education. Her work consistently emphasizes the importance of shifting perspectives—from short-term outcomes to long-term health and from traditional leadership models to more inclusive and forward-thinking approaches.
Lynn’s leadership philosophy is rooted in courage, collaboration, and accountability. She is known for challenging conventional thinking while fostering environments where teams feel empowered to innovate and execute. Her ability to balance strategic vision with operational discipline has made her a trusted advisor to executive teams and boards alike.
Her international experience, spanning the United States, Denmark, Switzerland, and emerging markets, has shaped her global perspective. She brings a nuanced understanding of how cultural, regulatory, and economic factors influence healthcare delivery and market access. This perspective allows her to guide organizations through complexity with clarity and confidence.
At her core, Lynn is driven by purpose. She is deeply committed to advancing women’s health, improving outcomes in obesity and metabolic disease, and mentoring the next generation of leaders. Her passion extends beyond the boardroom into community impact, including her involvement in nonprofit initiatives supporting youth and individuals with disabilities.
Lynn Sullivan’s career is not simply a record of achievements—it is a blueprint for how visionary leadership can transform industries. By consistently aligning innovation with execution, she has helped shape the future of biopharma and continues to influence the next wave of growth and discovery.
Character:
Lynn demonstrates unwavering integrity and resilience in every leadership role she undertakes. She consistently leads with authenticity, fostering trust among colleagues, stakeholders, and partners. Her commitment to purpose-driven work reflects a deep sense of responsibility to both patients and the organizations she serves.
Knowledge:
She possesses extensive expertise across commercialization, global markets, and therapeutic innovation. Her deep understanding of obesity, cardiometabolic disease, and women’s health allows her to identify opportunities others may overlook. She continuously builds on her knowledge through experience, ensuring she remains at the forefront of industry evolution.
Strategic:
Lynn excels at transforming complex challenges into clear, actionable strategies. She has a proven ability to identify white space opportunities and build scalable business models that drive growth. Her strategic mindset enables organizations to move from vision to execution with precision and confidence.
Communication:
A compelling communicator who connects strategy to action with clarity and purpose. She engages diverse audiences—from boardrooms to global conferences—with confidence and authenticity. Her ability to inspire and align teams ensures that vision translates into measurable results.
